Aptarion Biotech AG specializes in the development of innovative treatments for life-threatening diseases, utilizing the unique properties of mirror-image L-aptamers. These L-aptamers are single-stranded L-RNA or L-DNA molecules engineered to bind and inhibit pharmacologically relevant targets, offering a therapeutic approach comparable to monoclonal antibodies. The advantages of L-aptamers include high target affinity and specificity, enhanced biostability, low immunogenicity, and a scalable chemical production process, making them a promising platform for drug development.

The company's lead drug candidate, AON-D21, is currently undergoing a Phase 2 clinical trial involving 100 patients with severe community-acquired pneumonia. This highlights Aptarion's commitment to advancing its L-aptamer technology in clinical settings, aiming to provide effective treatments for serious health conditions. By focusing on the unique characteristics of L-aptamers, Aptarion Biotech AG is positioned to make significant contributions to the field of biopharmaceuticals.

Germany

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

Aptarion biotech AG

Company Details